Beryl Drugs Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 61.1 million compared to INR 34.69 million a year ago. Revenue was INR 60.93 million compared to INR 35.2 million a year ago. Net income was INR 0.632 million compared to net loss of INR 4.74 million a year ago. Basic earnings per share from continuing operations was INR 0.12 compared to basic loss per share from continuing operations of INR 0.94 a year ago. Diluted loss per share from continuing operations was INR 0.36 compared to INR 0.94 a year ago.
For the full year, sales was INR 268.88 million compared to INR 146.04 million a year ago. Revenue was INR 271.57 million compared to INR 147.69 million a year ago. Net income was INR 7.66 million compared to net loss of INR 6.59 million a year ago. Basic earnings per share from continuing operations was INR 1.52 compared to basic loss per share from continuing operations of INR 1.3 a year ago. Diluted earnings per share from continuing operations was INR 1.52 compared to diluted loss per share from continuing operations of INR 1.3 a year ago.